Ildong Pharm (KRX: 249420)
Who is buying Ildong Pharm?
Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net bought ₩0.7bn ($1M) of Ildong Pharm, the 142nd largest foreign net purchase among 832 KOSPI stocks. Institutions net sold ₩0.6bn ($0M) and retail investors net sold ₩0.2bn ($0M) over the same window. Foreigners were net buyers on 9 of the 20 sessions.
Foreign investors hold 5.21% of Ildong Pharm's listed shares (KRX ownership data as of Oct 13, 2026), down from 5.53% twenty sessions earlier and 4.04% a year ago.
The stock closed at ₩13,240 on Oct 13, 2026: -16.94% over 20 sessions, -65.61% year-to-date, -46.18% over one year. The 52-week range is ₩11,250 – ₩45,050.
At ₩13,240 the stock trades at 14.06× trailing earnings (KRX, last completed fiscal year); no analyst consensus is available for a forward P/E.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-13 | ₩13,240 | +₩0.5bn | +₩0.0bn | ₩-0.5bn |
| 2026-10-12 | ₩13,580 | +₩0.3bn | +₩0.0bn | ₩-0.3bn |
| 2026-10-08 | ₩14,020 | ₩-0.4bn | ₩-0.0bn | +₩0.5bn |
| 2026-10-07 | ₩14,810 | ₩-1.0bn | ₩0.0bn | +₩1.0bn |
| 2026-10-06 | ₩14,730 | +₩0.5bn | +₩0.0bn | ₩-0.6bn |
| 2026-10-02 | ₩14,510 | ₩-0.2bn | ₩-0.0bn | +₩0.2bn |
| 2026-10-01 | ₩14,570 | +₩1.5bn | ₩-0.0bn | ₩-1.5bn |
| 2026-09-30 | ₩13,950 | +₩0.8bn | ₩-0.0bn | ₩-0.8bn |
| 2026-09-29 | ₩13,770 | +₩0.4bn | ₩-0.0bn | ₩-0.4bn |
| 2026-09-28 | ₩14,060 | +₩0.9bn | ₩-0.0bn | ₩-0.9bn |
| 2026-09-23 | ₩13,840 | ₩-0.1bn | ₩-0.0bn | +₩0.1bn |
| 2026-09-22 | ₩14,010 | ₩-0.1bn | ₩-0.0bn | +₩0.2bn |
| 2026-09-21 | ₩14,140 | ₩-0.4bn | +₩0.0bn | +₩0.4bn |
| 2026-09-18 | ₩14,320 | ₩-0.5bn | +₩0.0bn | +₩0.5bn |
| 2026-09-17 | ₩14,460 | +₩0.8bn | +₩0.0bn | ₩-0.8bn |
| 2026-09-16 | ₩14,420 | ₩-0.2bn | +₩0.0bn | +₩0.2bn |
| 2026-09-15 | ₩14,900 | +₩0.2bn | ₩-0.1bn | ₩-0.2bn |
| 2026-09-14 | ₩14,990 | ₩-0.4bn | +₩0.0bn | +₩0.5bn |
| 2026-09-11 | ₩15,320 | ₩-0.6bn | ₩-0.0bn | +₩0.5bn |
| 2026-09-10 | ₩15,520 | ₩-1.2bn | ₩-0.5bn | +₩1.7bn |
| 2026-09-09 | ₩15,940 | ₩-1.4bn | +₩0.0bn | +₩1.5bn |
| 2026-09-08 | ₩15,940 | ₩-2.6bn | +₩0.0bn | +₩2.3bn |
| 2026-09-07 | ₩15,040 | ₩-0.1bn | ₩-0.7bn | +₩0.8bn |
| 2026-09-04 | ₩15,030 | ₩-0.4bn | +₩0.0bn | +₩0.4bn |
| 2026-09-03 | ₩15,100 | ₩-6.4bn | ₩-0.1bn | +₩6.6bn |
| 2026-09-02 | ₩16,490 | ₩-8.2bn | ₩-0.1bn | +₩8.3bn |
| 2026-09-01 | ₩14,500 | ₩-0.4bn | ₩-0.0bn | +₩0.4bn |
| 2026-08-31 | ₩14,770 | ₩-1.0bn | +₩0.0bn | +₩1.1bn |
| 2026-08-28 | ₩14,840 | ₩-0.6bn | +₩0.0bn | +₩0.6bn |
| 2026-08-27 | ₩14,360 | ₩-1.9bn | ₩-0.1bn | +₩2.0bn |
| 2026-08-26 | ₩15,040 | +₩2.0bn | +₩0.0bn | ₩-2.1bn |
| 2026-08-25 | ₩14,230 | ₩-2.6bn | ₩-0.0bn | +₩2.5bn |
| 2026-08-24 | ₩15,150 | ₩-5.7bn | +₩0.2bn | +₩5.6bn |
| 2026-08-21 | ₩13,510 | ₩-0.9bn | +₩0.0bn | +₩0.9bn |
| 2026-08-20 | ₩14,480 | +₩0.2bn | +₩0.0bn | ₩-0.3bn |
| 2026-08-19 | ₩13,850 | ₩-0.2bn | +₩0.0bn | +₩0.1bn |
| 2026-08-18 | ₩14,170 | ₩-1.5bn | ₩-0.0bn | +₩1.6bn |
| 2026-08-14 | ₩15,200 | ₩-0.3bn | +₩0.0bn | +₩0.3bn |
| 2026-08-13 | ₩15,220 | +₩0.6bn | ₩-1.1bn | +₩0.6bn |
| 2026-08-12 | ₩15,260 | ₩-0.3bn | +₩0.0bn | +₩0.2bn |
| 2026-08-11 | ₩15,570 | ₩-0.2bn | ₩-1.1bn | +₩1.2bn |
| 2026-08-10 | ₩15,890 | +₩0.5bn | +₩0.0bn | ₩-0.5bn |
| 2026-08-07 | ₩15,320 | ₩-0.3bn | +₩0.0bn | +₩0.3bn |
| 2026-08-06 | ₩15,330 | +₩0.0bn | +₩0.0bn | ₩-0.1bn |
| 2026-08-05 | ₩14,990 | ₩-0.2bn | ₩-0.0bn | +₩0.2bn |
| 2026-08-04 | ₩14,760 | +₩0.3bn | +₩0.0bn | ₩-0.4bn |
| 2026-08-03 | ₩14,050 | +₩0.3bn | +₩0.0bn | ₩-0.4bn |
| 2026-07-31 | ₩13,730 | +₩0.5bn | ₩-0.1bn | ₩-0.4bn |
| 2026-07-30 | ₩12,590 | +₩0.6bn | ₩-0.0bn | ₩-0.6bn |
| 2026-07-29 | ₩12,150 | +₩0.6bn | ₩-0.1bn | ₩-0.5bn |
| 2026-07-28 | ₩13,170 | +₩0.2bn | +₩0.0bn | ₩-0.2bn |
| 2026-07-27 | ₩14,060 | ₩-0.0bn | +₩0.0bn | +₩0.0bn |
| 2026-07-24 | ₩13,960 | ₩-0.4bn | +₩0.0bn | +₩0.4bn |
| 2026-07-23 | ₩13,920 | +₩0.4bn | ₩-0.2bn | ₩-0.2bn |
| 2026-07-22 | ₩13,450 | ₩-0.2bn | +₩0.0bn | +₩0.1bn |
| 2026-07-21 | ₩13,600 | +₩0.4bn | ₩-0.1bn | ₩-0.3bn |
| 2026-07-20 | ₩13,490 | ₩-0.0bn | ₩-0.0bn | +₩0.0bn |
| 2026-07-16 | ₩14,230 | +₩0.0bn | +₩0.1bn | ₩-0.1bn |
| 2026-07-15 | ₩14,390 | +₩0.9bn | ₩-0.1bn | ₩-0.8bn |
| 2026-07-14 | ₩13,670 | +₩0.3bn | ₩-0.1bn | ₩-0.2bn |
| 2026-07-13 | ₩14,510 | ₩-0.3bn | ₩-0.0bn | +₩0.3bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | +₩0.5bn | +$0M | +₩0.0bn | ₩-0.5bn |
| 5 days | ₩-0.1bn | $-0M | +₩0.1bn | +₩0.1bn |
| 20 days | +₩0.7bn | +$1M | ₩-0.6bn | ₩-0.2bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying Ildong Pharm stock?
Over the last 5 sessions foreign investors net sold ₩0.1bn ($0M) of Ildong Pharm; over 60 sessions they net sold ₩27.2bn ($20M); since Jan 1, 2026 they net bought ₩18.9bn ($14M). Over 20 sessions the stock is the 142nd largest foreign net purchase among 832 KOSPI stocks.
How much of Ildong Pharm do foreign investors own?
Foreign investors own 5.21% of Ildong Pharm's shares as of Oct 13, 2026, versus 4.04% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net sold ₩0.6bn ($0M) and retail investors net sold ₩0.2bn ($0M) of Ildong Pharm. Foreign buying is being met mainly by retail selling.
Is Ildong Pharm listed on KOSPI or KOSDAQ?
Ildong Pharm (일동제약) trades on KOSPI under KRX code 249420 in the Biotech & Pharma group, with a market capitalization of ₩0T ($0.3B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2023 | ₩601bn ($451M) | – | -₩54bn (-$40M) | -₩81bn (-$61M) |
| 2024 | ₩615bn ($461M) | +2.40% | ₩13bn ($10M) | -₩12bn (-$9M) |
| 2025 | ₩567bn ($425M) | -7.80% | ₩19bn ($15M) | ₩24bn ($18M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.